EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Deep molecular response in patients with chronic phase chronic myeloid leukemia treated with the plasminogen activator inhibitor‐1 inhibitor TM5614 combined with a tyrosine kinase inhibitor

Naoto Takahashi iD, Yoshihiro Kameoka, Makoto Onizuka, Yasushi Onishi, Fumiaki Takahashi, Takashi Dan, Toshio Miyata, Kiyoshi Ando, Hideo Harigae

Cancer Medicine · 2023-02 · 12 (4) · 4250-4258

DOI: 10.1002/cam4.5292 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 23.09.2022. Verfasst von Naoto Takahashi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Akita University School of Medicine, Akita, Japan. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Chronic-Phase, Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We recently showed that pharmacological inhibition of plasminogen activator inhibitor‐1 (PAI‐1) activity, based on TM5614, increases cell motility and induces the detachment of hematopoietic stem cells from their niches. In this TM5614 phase II clinical trial, we investigated whether the combination of a PAI‐1 inhibitor and tyrosine kinase inhibitors (TKIs) would induce a deep molecular response (DMR) in patients affected by chronic myeloid leukemia (CML) by quantifying BCR‐ABL1 transcripts.

Methods

Patients with chronic phase CML treated with a stable daily dose of TKIs for at least 1 year and yielding a major molecular response (MMR) but not achieving MR 4.5 were eligible for this study. After inclusion, patients began to receive TM5614 as well as a TKI. The primary objective was an evaluation of the cumulative incidence of patient progression from an MMR/MR 4 to MR 4.5 by 12 months.

Results

Thirty‐three patients were enrolled in the study. The median age was 59.0 years and 58% were male. No Sokal high‐risk patients were enrolled in this trial. The median TKI treatment duration was 4.8 years. At the start of this study, seven patients and 26 patients received imatinib and second‐generation TKIs, respectively. The cumulative MR 4.5 incidence by 12 months was 33.3% (95% confidence interval, 18.0%–51.8%). The cumulative MR 4.5 spontaneous conversion over 12 months was estimated as 8% with TKIs alone based on historical controls. The halving time of BCR‐ABL1 at 2 months was significantly shorter for patients who achieved an MR 4.5 , by 12 months than for the other patients (cutoff value: 48 days; sensitivity: 0.80; specificity: 0.91; ROC‐AUC: 0.83). During this study, bleeding events and abnormal coagulation related to the drug were not reported, and TM5614 was found to be highly safe.

Conclusion

TM5614 combined with TKI was well tolerated and induced MR 4.5 in more patients than stand‐alone TKI treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, Chronic-PhaseLeukemia, Myelogenous, Chronic, BCR-ABL PositiveHumansMaleMiddle AgedFemaleTyrosine Kinase InhibitorsFusion Proteins, bcr-ablPlasminogen Activator Inhibitor 1Protein Kinase Inhibitors

Stichwörter der Autor:innen

BCR-ABL1PAI-1 inhibitorchronic myeloid leukemiatyrosine kinase inhibitor

Substanzen

Tyrosine Kinase InhibitorsFusion Proteins, bcr-ablPlasminogen Activator Inhibitor 1Protein Kinase Inhibitors

Autor:innen und Institutionen

  • Akita University School of Medicine, Akita, Japan.
  • Tokai University School of Medicine, Isehara, Japan.
  • Tohoku University, Sendai, Japan.
  • Iwate Medical University, Morioka, Japan.
  • Renascience Inc., Tokyo, Japan.

ORCID-Profile: Naoto Takahashi

Förderung

  • Japan Agency for Medical Research and Development

Zitieren

APA

Takahashi, N., Kameoka, Y., Onizuka, M., Onishi, Y., Takahashi, F., Dan, T., Miyata, T., Ando, K., & Harigae, H. (2023). Deep molecular response in patients with chronic phase chronic myeloid leukemia treated with the plasminogen activator inhibitor‐1 inhibitor TM5614 combined with a tyrosine kinase inhibitor. Cancer Medicine, 12(4), 4250-4258. https://doi.org/10.1002/cam4.5292

Vancouver

Takahashi N, Kameoka Y, Onizuka M, Onishi Y, Takahashi F, Dan T, et al. Deep molecular response in patients with chronic phase chronic myeloid leukemia treated with the plasminogen activator inhibitor‐1 inhibitor TM5614 combined with a tyrosine kinase inhibitor. Cancer Medicine. 2023;12(4):4250-4258. doi:10.1002/cam4.5292

BibTeX
@article{Takahashi2023,
  author = {Takahashi, Naoto and Kameoka, Yoshihiro and Onizuka, Makoto and Onishi, Yasushi and Takahashi, Fumiaki and Dan, Takashi and Miyata, Toshio and Ando, Kiyoshi and Harigae, Hideo},
  title = {Deep molecular response in patients with chronic phase chronic myeloid leukemia treated with the plasminogen activator inhibitor‐1 inhibitor TM5614 combined with a tyrosine kinase inhibitor},
  journal = {Cancer Medicine},
  year = {2023},
  volume = {12},
  number = {4},
  pages = {4250--4258},
  doi = {10.1002/cam4.5292}
}
Kostenlos starten →